Roughly 38 million Americans have diabetes, and about 90 to 95 percent of them have type 2. Another 96 million have prediabetes. Type 2 diabetes is a chronic condition that develops when the body becomes resistant to insulin and the pancreas cannot keep up with demand. The good news is that the playbook for managing it has improved enormously in the last decade — especially with the arrival of GLP-1 receptor agonists, which produce weight loss and cardiovascular benefits no oral medication previously offered.
Type 2 diabetes is well-suited to telehealth management. The diagnosis is based on labs (A1c, fasting glucose, oral glucose tolerance) rather than physical examination, treatment involves medication and lifestyle adjustment, and ongoing management benefits from frequent low-friction check-ins to adjust the plan.
When to seek emergency care immediately
- DKA signs — nausea, vomiting, abdominal pain, fruity breath, deep rapid breathing, fatigue, very high glucose. More common in type 1 but can occur in type 2 with illness.
- Severe hypoglycemia — confusion, loss of consciousness, seizure. Treat with rapid-acting carbohydrate (15 g) or glucagon if available.
- Hyperosmolar hyperglycemic state — very high glucose (>600), dehydration, altered mental status. ER, not telehealth.
- Severe foot infection or ulcer in a person with diabetes — risk of progression to sepsis or amputation. In-person same day.
Treatment Goals: A1c and Beyond
The American Diabetes Association recommends individualized A1c targets. For most non-pregnant adults the goal is below 7 percent. For older adults with multiple comorbidities, looser targets (7.5 to 8 percent) reduce hypoglycemia risk. For younger patients with new diagnoses and few complications, tighter targets (below 6.5 percent) may be appropriate.
A1c is only one piece. Equally important targets:
- Blood pressure — below 130/80 for most people with diabetes
- LDL cholesterol — below 70 mg/dL for those with established cardiovascular disease, below 100 mg/dL for everyone else with diabetes
- Weight — a 5 to 10 percent loss often produces large A1c improvements
- Annual screenings — eye exam, foot exam, kidney function (eGFR + urine albumin/creatinine ratio)
Lifestyle — the Most Underrated Intervention
The Diabetes Prevention Program showed that a 7 percent weight loss plus 150 minutes of moderate exercise per week reduced progression from prediabetes to diabetes by 58 percent — outperforming metformin. The same principles apply to managing established type 2 diabetes:
- Carbohydrate awareness. The biggest lever for daily glucose. Lower-carb diets (Mediterranean, plate method, or even strict low-carb) consistently improve A1c. We do not push a specific diet — we work with what is sustainable for you.
- Exercise. 150 minutes per week of moderate activity, ideally with some resistance training. Even short walks after meals reduce post-meal glucose spikes.
- Weight loss. A 5 to 10 percent weight loss often drops A1c by 0.5 to 1 percent. GLP-1 medications can help when lifestyle alone is not enough.
- Sleep. Short sleep worsens insulin resistance.
Metformin: Still the First-Line Medication
Metformin remains first-line per ADA and AACE guidelines for most patients with newly diagnosed type 2 diabetes. It works by reducing hepatic glucose production, is inexpensive, has decades of safety data, and is associated with modest weight loss rather than gain. Typical dosing starts at 500 mg with the largest meal, titrated to 1000 mg twice daily over 4 to 6 weeks. The extended-release form reduces the GI side effects (nausea, diarrhea) that limit tolerance for some patients.
Metformin is contraindicated in advanced kidney disease (eGFR below 30) and should be used cautiously between 30 and 45.
GLP-1 Receptor Agonists: The Game-Changer
GLP-1 agonists have transformed type 2 diabetes care. They lower glucose, produce significant weight loss (typically 10 to 20 percent for tirzepatide), reduce cardiovascular events, and slow progression of chronic kidney disease. Current options:
- Semaglutide (Ozempic, Wegovy, Rybelsus). Once-weekly injection or daily oral. Weight loss averages 10 to 15 percent. Cardiovascular benefit in patients with established CV disease.
- Tirzepatide (Mounjaro, Zepbound). A dual GLP-1/GIP agonist. Once-weekly injection. Weight loss averages 15 to 20 percent. Largest A1c reductions of any non-insulin medication.
- Dulaglutide (Trulicity), Liraglutide (Victoza). Older GLP-1 options, less weight loss than the newer agents but still effective.
Side effects are mainly GI — nausea, occasional vomiting, constipation — usually mild and fading after the first 4 to 8 weeks. Rare but serious: pancreatitis, gallstones, severe gastroparesis. Cost and supply remain challenges; we help you navigate manufacturer savings programs.
SGLT2 Inhibitors and Other Options
- SGLT2 inhibitors (empagliflozin, dapagliflozin). Promote glucose excretion in urine. Provide cardiovascular and kidney-protection benefits, especially in patients with heart failure or chronic kidney disease. Risk of genital yeast infections and rare DKA.
- DPP-4 inhibitors (sitagliptin). Weight-neutral, well-tolerated, modest A1c reduction. Lower priority than GLP-1s in patients who would benefit from weight loss.
- Sulfonylureas (glipizide, glimepiride). Older oral medications. Inexpensive but cause hypoglycemia and weight gain. Used less often now.
- Insulin. Sometimes needed when oral and injectable non-insulin medications are not enough, or in acute settings. Basal-only regimens (long-acting insulin once daily) are usually the starting point.
Monitoring — What and How Often
- A1c every 3 to 6 months until at goal; every 6 to 12 months when stable.
- Home glucose monitoring. Patients on insulin or sulfonylureas should check. Most other patients can use intermittent or continuous glucose monitoring (CGM) to learn how meals affect them, but it is not required.
- Annual labs. Lipid panel, kidney function (eGFR, urine albumin), liver enzymes.
- Annual screenings. Dilated eye exam, comprehensive foot exam. Telehealth cannot do these — we refer to local optometry and podiatry.
When Telehealth Works and When It Doesn't
Telehealth is excellent for routine type 2 diabetes management: lab ordering, medication titration, lifestyle counseling, refills, GLP-1 initiation and dose adjustments. We coordinate annual in-person screenings with local providers.
Telehealth is not the right setting for:
- New diagnosis with severe symptoms or very high A1c (above 10) — often needs in-person evaluation first
- Acute illness with vomiting, dehydration, or signs of DKA
- Foot ulcers or active infection
- Insulin pump troubleshooting or CGM hardware issues
- Type 1 diabetes — specialist-led care is preferred
Bottom line. Modern type 2 diabetes care looks very different from a decade ago. Metformin plus a GLP-1 agonist is now the default for most patients who can tolerate it, with SGLT2 inhibitors added for cardiovascular or kidney protection. Lifestyle changes still drive most of the long-term success, and most management decisions happen between visits as you learn how your body responds.
Frequently Asked Questions
Can type 2 diabetes be managed without insulin?
Yes. Many patients with type 2 diabetes achieve excellent blood sugar control through oral medications like metformin, injectable GLP-1 receptor agonists, dietary modifications, and regular exercise. Whether insulin is needed depends on factors like A1C levels, how long you have had diabetes, and how your body responds to other treatments.
What is a good A1C target for type 2 diabetes?
For most adults with type 2 diabetes, an A1C target of less than 7% is recommended. However, your provider may set a more or less aggressive target based on your age, other health conditions, hypoglycemia risk, and overall life expectancy. An A1C of 6.5% to 7% indicates well-controlled diabetes.
How does metformin work for diabetes?
Metformin works primarily by reducing the amount of glucose your liver produces and by improving your body's sensitivity to insulin. It does not cause low blood sugar (hypoglycemia) when used alone and is weight-neutral or may promote modest weight loss. It is the recommended first-line medication for type 2 diabetes.
What foods should I avoid with type 2 diabetes?
Focus on limiting refined carbohydrates (white bread, sugary cereals, pastries), sugar-sweetened beverages, processed foods high in added sugars, and large portions of starchy foods. Rather than strict avoidance, aim for a balanced approach emphasizing vegetables, lean proteins, whole grains, and healthy fats while monitoring portion sizes of carbohydrate-containing foods.
Can I manage my diabetes through telehealth?
Yes. Telehealth is well-suited for diabetes management including medication adjustments, A1C result review, lifestyle counseling, and ongoing monitoring. InnoCre Health provides diabetes care via telehealth for patients in Maryland, Washington, and Delaware at $68 per visit with HSA/FSA accepted.
Can type 2 diabetes be reversed?
Type 2 diabetes can sometimes be put into remission, particularly when caught early, through sustained weight loss, dietary changes, and physical activity. Remission means A1C stays below 6.5 percent for at least three months without diabetes medications. However, the underlying tendency persists, so monitoring and ongoing lifestyle habits remain important.
What are GLP-1 medications like Ozempic and Mounjaro?
GLP-1 receptor agonists such as semaglutide (Ozempic) and tirzepatide (Mounjaro) are injectable medications that lower blood sugar, slow gastric emptying, and reduce appetite. They are approved for type 2 diabetes and provide cardiovascular and kidney benefits. Common side effects include nausea, especially when starting or increasing the dose.
How often should I check my blood sugar at home?
Frequency depends on your medications. If you take only oral medications and your A1C is stable, checking once daily or a few times a week may be enough. If you are on insulin or sulfonylureas, more frequent checks (before meals and bedtime) are typically recommended. Continuous glucose monitors are also an option for tighter tracking.
What blood sugar number is considered dangerously high?
Blood sugars over 240 mg/dL persistently warrant a call to your provider, especially with symptoms such as nausea, fruity breath, or confusion. Levels above 400 mg/dL or any sign of diabetic ketoacidosis (vomiting, deep rapid breathing, severe dehydration) require emergency evaluation. Telehealth is not appropriate for acute hyperglycemic emergencies.
Can adolescents be diagnosed with type 2 diabetes?
Yes, type 2 diabetes is increasingly diagnosed in adolescents, often related to rising rates of obesity. InnoCre treats adolescents age 12 and older in MD, WA, and DE and can coordinate lifestyle interventions and certain medications. Complex pediatric cases or those requiring specialty input may be co-managed with an endocrinologist.
Ready to see a provider?
Book a same-day telehealth visit with a board-certified provider from home.
Book a Visit →Same-day visits · HSA/FSA accepted · Licensed in MD, WA & DE
Atul S. Vellappally, DNP, CRNP, FNP-BC
Founder, Innocre Telehealth. Board-certified Family Nurse Practitioner with doctoral-level training in evidence-based and precision medicine. Licensed in Maryland, Washington, and Delaware.
This article is for informational purposes only and does not constitute medical advice. If you are experiencing a medical emergency, call 911.
Related Articles
Sources
- American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
- Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
- Colberg SR, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the ADA. Diabetes Care. 2016;39(11):2065-2079.
- Evert AB, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019;42(5):731-754.
Related Services